Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development

被引：70

作者：

Fennell, DA

Rudd, RM

机构：

[1] Univ London St Bartholomews Hosp Med Coll, Dept Med Oncol, London EC1A 7BE, England

[2] Univ London St Bartholomews Hosp Med Coll, Lung Canc & Mesothelioma Res Grp, London EC1A 7BE, England

来源：

LANCET ONCOLOGY | 2004年 / 5卷 / 06期

关键词：

D O I：

10.1016/S1470-2045(04)01492-5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Because of a lack of effective treatments, survival from diffuse pleural mesothelioma remains poor. Many people do not think that treatments for this disease are effective. The understanding of the biology of mesothelioma relevant to the apoptosis-resistant phenotype has been slow to advance. However, this is now changing, and strategies for rational therapeutic drug development are emerging that have the potential to change the natural history and improve survival in the increasing number of patients that will be diagnosed in the next two decades. This review discusses recent developments in apoptosis biology that are specific to mesothelioma and the therapeutic implications for this aggressive cancer.

引用

页码：354 / 362

页数：9

共 60 条

[51]

Soini Y, 1999, CLIN CANCER RES, V5, P3508

[52] Phase II study of vinorelbine in patients with malignant pleural mesothelioma [J].